The Conversation (0)
VistaGen Therapeutics shared the publication of two Phase 1 clinical studies of the effects of AV-101, the company’s candidate for a potential non-opioid treatment for neuropathic pain, in a peer-reviewed paper.
VistaGen Therapeutics (NASDAQ:VTGN) shared the publication of two Phase 1 clinical studies of the effects of AV-101, the company’s candidate for a potential non-opioid treatment for neuropathic pain, in a peer-reviewed paper.
As quoted in the press release:
Safety data from both the single and multi-dose Phase 1 studies indicated that oral AV-101 was extremely safe and well tolerated, with no meaningful difference in adverse events (AEs) at any dose between AV-101 and placebo. Recently published statistically-significant positive results in four well-established preclinical models of pain associated with tissue inflammation and nerve injury, together with the excellent clinical safety profile, pharmacokinetic (PK) characteristics and consistent reductions in three pain measures (allodynia, mechanical and heat hyperalgesia) demonstrated by these studies, support future Phase 2 clinical studies of AV-101 as a potential new non-opioid treatment alternative for neuropathic pain.
“The excellent safety data and consistent reductions in allodynia pain and mechanical and heat hyperalgesia during the two Phase 1 clinical studies of AV-101 support our belief in its potential to treat neuropathic pain without the negative side-effects experienced with most of the drugs used today to treat pain. Additional clinical trials of AV-101 in neuropathic pain are warranted,” reported Mark Wallace, MD, Distinguished Professor of Clinical Anesthesiology at the University of California, San Diego.
Click here to read the full press release.
Source: www.marketwired.com
